PDCD1 and Miyoshi myopathy: Moreover, we observed a median OSPO of 19 months (range 11–25; 95% C.I.)and a median OS of 38 months (16–38 95% C.I.), which are much longer than those reported in previous MM TBP experience both with BRAF inhibitors [22,23], which reported a median OSPO and a median OS ranging from 5.2 to 11.6 and 12.8 to 26 months, respectively, and with PD1 blockade documenting a median OS of 24.4 months [25] and a rate of 24-month survivors of 59% [24].